

17 June 2013

1- 000001 000 HIN
MR SAM SAMPLE
UNIT 123
SAMPLE STREET
SAMPLETOWN NSW 2001

Dear HeartWare CDI Holder,

When we first listed our shares in Australia during 2005, our small company was just beginning to see positive results from our efforts to develop a new generation of devices designed to assist advanced heart failure patients. We had plans to commence an international clinical trial, with hospital sites in Australia and Europe. We hoped that study would lead to commercialization, and that we would be able to build on that success and expand globally.

Investors in Australia shared our vision for the potential of our company. Being publicly traded on the ASX provided us with a vehicle to fund HeartWare's research and development efforts. Together we have endured challenging times and celebrated exciting milestones, as we have worked to advance our product portfolio. Today, more than 3,000 advanced heart failure patients in 30 countries around the globe have received our first device, the HeartWare® Ventricular Assist System. Through the emergence of HeartWare as one of the leading companies in the field of mechanical circulatory support, we have appreciated the strong support of our ASX investors.

However, since HeartWare's listing on NASDAQ in 2009, there has been a substantial shift in the trading volume of our securities from ASX to NASDAQ, which has culminated in more than 99% of the total trading volume of our securities occurring on NASDAQ and less than 1% of the trading volume occurring on ASX. In addition, CDIs in Australia now only represent approximately 5% of our issued and outstanding capital. As a result, and after careful consideration, we have determined that sustaining the administrative costs of an ASX listing, including the higher level of regulatory compliance costs associated with dual listings, is difficult to justify and, accordingly, have made the decision to delist from ASX.

As you will see from the enclosed information, our team has worked to create a methodical timetable and structure to facilitate this process. Please review the attached information, utilize the resources described, as well as seek guidance from your financial advisor, to make the most appropriate decisions for you. And of course, please feel free to contact us if you have any questions about HeartWare or if you would like additional assistance.

We could not have attained such success without our ASX investors, and we have sincerely appreciated your support.

On behalf of the entire HeartWare team, thank you.

Respectfully yours,



Doug Godshall
President and CEO
HeartWare International, Inc.



Ray Larkin
Chairman, Board of Directors
HeartWare International, Inc.

168194_01GF9A